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Abstract
Dietary, pharmacological and genetic interventions can extend health- and lifespan in
diverse mammalian species. DNA methylation has been implicated in mediating the benefi-
cial effects of these interventions; methylation patterns deteriorate during ageing, and this is
prevented by lifespan-extending interventions. However, whether these interventions also
actively shape the epigenome, and whether such epigenetic reprogramming contributes
to improved health at old age, remains underexplored. We analysed published, whole-
genome, BS-seq data sets from mouse liver to explore DNA methylation patterns in aged
mice in response to three lifespan-extending interventions: dietary restriction (DR), reduced
TOR signaling (rapamycin), and reduced growth (Ames dwarf mice). Dwarf mice show
enhanced DNA hypermethylation in the body of key genes in lipid biosynthesis, cell prolifer-
ation and somatotropic signaling, which strongly correlates with the pattern of transcriptional
repression. Remarkably, DR causes a similar hypermethylation in lipid biosynthesis genes,
while rapamycin treatment increases methylation signatures in genes coding for growth fac-
tor and growth hormone receptors. Shared changes of DNA methylation were restricted to
hypermethylated regions, and they were not merely a consequence of slowed ageing, thus
suggesting an active mechanism driving their formation. By comparing the overlap in age-
ing-independent hypermethylated patterns between all three interventions, we identified
four regions, which, independent of genetic background or gender, may serve as novel bio-
markers for longevity-extending interventions. In summary, we identified gene body hyper-
methylation as a novel and partly conserved signature of lifespan-extending interventions in
mouse, highlighting epigenetic reprogramming as a possible intervention to improve health
at old age.
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Author summary
Dietary, genetic and pharmacological interventions can extend lifespan in diverse organ-
isms and represent good models for developing therapies against age-related diseases in
humans. However, whether these longevity interventions act by slowing down the effects
of ageing, or inducing novel phenotypes to cope better with age-related stress, remains
unclear. The epigenome is influenced by many factors including diet, drugs and genetic
mutations, making it a possible candidate for linking longevity interventions. Here, we
conducted a meta-analysis of published mouse liver datasets to profile changes in DNA
methylation in response to three lifespan-extending interventions: reduced food intake,
the drug rapamycin and a genetic mutation causing dwarfism. In dwarf mice, there was
enhanced DNA methylation over specific genes involved in fatty metabolism and growth
factor signaling. Reduced food intake and rapamycin treatment shared DNA methylation
patterns with dwarf mice, revealing similar influences on the epigenome. Hypermethy-
lated genes were also less active, which may protect dwarf and DR mice against liver stea-
tosis and cancer. In addition, we developed novel DNA methylation biomarkers that
could potentially predict longevity-extending interventions.
Introduction
Dietary, genetic and pharmacological interventions can extend health- and lifespan in diverse
model organisms whilst delaying the onset of age-related pathologies [1–3]. Understanding
the underlying mechanisms holds the prospect of harnessing these benefits for prevention of
age-related diseases in humans [3]. Dietary restriction (DR), in which food intake is reduced
while avoiding malnutrition, is currently the most effective intervention to increase lifespan
and health during ageing. DR extends lifespan in rodents and [2,4,5] improves health in pri-
mates [6–8] whilst protecting against age-related diseases such as cancer and diabetes [1,9,10].
In mice and rats, DR improves health- and lifespan also when applied in adult animals [11,12],
demonstrating that the effects of DR are not result of altered development. Although the exact
mediators remain elusive [13,14], studies in animal models have identified crucial roles of the
regulatory, nutrient-sensing insulin/insulin-like growth factor/mTOR network [15–17] for
improved health by DR. DR is further implicated to act through the somatotropic axis, an
endocrine network regulating body growth via secretion of growth hormone (GH) from the
pituitary gland and the downstream release of insulin-like growth factor (IGF-1) from the liver
[15,18–21]. The specific molecular and physiological consequences of DR are, however, depen-
dent on experimental variables including genetic background [10,22], gender [10,23] and food
composition [2,7,24].
Consistent with its central role in DR-mediated longevity, genetically reduced somatotropic
signaling can extend lifespan in mice [25–27]. For instance, Ames dwarf mice carry a homozy-
gous mutation at the Prop1 locus, resulting in reduced GH secretion from the pituitary gland,
with consequently reduced levels of circulating IGF-1 [19,28]. In addition to decreased body
size, Ames dwarf mice exhibit high insulin sensitivity, increased stress resistance and delayed
onset of neoplasia, which is specifically caused by GH deficiency [9,28–31]. Reduced somato-
tropic signaling also improves health- and lifespan in adult mice, as shown by inducible
knockout of the Growth hormone receptor (GHR) [32] or antibody-mediated reduction of
the IGF-1 receptor [33]. Lowered GH signaling is further associated with reduced activity of
the mTOR network [34–37], which also has a well-established role in ageing [1,3]. Indeed,
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pharmacological inhibition of mTOR signaling via rapamycin increases lifespan in model
organisms including adult mice [3,38].
DNA methylation is an epigenetic modification with a role in regulating gene transcription
[39,40]. Methylation of CpG dinucleotides is prevalent in mammalian genomes, and is
regarded as a relatively stable mark that is heritable across somatic cell divisions [41]. During
ageing, however, the DNA methylation code slowly deteriorates, which may contribute to ero-
sion of transcriptional control and to age-related pathologies such as cancer [39,42–44]. High-
throughput analysis of human DNA methylation microarray data demonstrated that chrono-
logical and biological age are strongly correlated with methylation states of a few hundred
CpGs, known as the epigenetic clock [42,45].
Epigenetic clocks have recently been developed for mice, and they are remarkably deceler-
ated by DR, rapamycin treatment and reduced growth factor signaling [46–48]. In agreement
with these observations, whole genome bisulfite sequencing (WGBS-seq) studies in DR
[49,50], rapamycin-treated and Ames dwarf mice [50] demonstrated diminished age-related
methylation changes across the mouse genome, maintaining a youthful profile over enhancers,
promoters and heterochromatic regions [49,50]. Protection against age-related methylation
changes and slowing of epigenetic clocks have therefore been proposed to contribute to
healthy ageing. However, age-related changes in methylation pattern are largely uncorrelated
with age-related changes in RNA transcript profiles [49,50], and it is thus unclear whether pre-
vention of methylation changes has any functional consequences. In addition to slowing nor-
mal age-related changes, DR also causes hypermethylation in distinct regions of the genome.
These DR-specific changes occurred predominantly in gene bodies, associated robustly with
transcriptional repression, and the affected genes are enriched for key members of the lipo-
genic network controlled by Srebf1. Their methylation is paralleled by a healthier lipid profile,
marked by decreased hepatic triacylglyceride accumulation and less elongated triglyceride-
associated fatty acids [49].
In order to determine if changes in DNA methylation of genes in the lipogenic network are
a general feature of DR, we conducted a meta-analysis of published WGBS-seq data for liver
derived from two different strains of mice subjected to DR. We found strongly conserved
hypermethylation of lipogenic Srebf1-target genes such as Elovl6, Scd1 and Fasn, independent
of genetic background, thereby revealing a robust epigenetic signature of DR. We also re-ana-
lyzed WGBS-seq profiles of aged rapamycin-treated and Ames dwarf mice, and found that
DNA methylation is specifically remodeled in these interventions as well. Hyper- but not
hypo-methylated regions of the genome coincide among different interventions, and are pre-
dominantly located in gene bodies. These patterns are induced at young age and do not result
from delayed ageing alone, which points to an active mechanism driving their formation. Fur-
thermore, joint methylome profiling identifies a limited set of common hypermethylated
regions that could serve as a new DNA methylation-based biomarker for intervention out-
come, independent of genetic background and gender.
Functionally, Ames dwarf mice shared hypermethylation patterns with rapamycin-treated
mice over genes coding for signaling mediators of growth factors and growth hormone, whilst
also showing hypermethylation over the same lipogenic Srebf1-target genes as DR-fed mice. In
Ames dwarf mice specifically, we found extensive epigenetic silencing of the somatoropic sig-
naling axis, including hypermethylation of IGF-1 and oncogenic downstream targets Egfr and
Onecut1. Analysis of published RNA-seq data of DR and Ames dwarf mice further revealed
that hypermethylation patterns of gene bodies and RNA transcript profiles were strongly asso-
ciated, pointing to a potentially causative role of DNA methylation in changes in gene expres-
sion in geroprotective interventions.
DNA methylation and lifespan-extending interventions
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We thus found targeted epigenetic reprogramming to be a novel and partly conserved fea-
ture of DR, reduced TOR and reduced somatotropic signaling, and characterized how this
new epigenotype could causally improve health in old animals.
Results
Epigenetic remodeling of lipid metabolism in response to dietary
restriction is conserved across mouse strains
Lifespan-extending interventions such as DR shape the DNA methylome by delaying age-
related methylation changes across the genome [49–52]. Long-term DR has further been
shown to alter DNA methylation specifically over lipid metabolism genes in C3B6F1 hybrid
mice. This epigenetic remodeling was induced already in young DR animals, becoming more
marked in older animals and differed from the pattern of age-related methylation changes
[49]. As these DR-related DNA methylation changes have so far only been described for
C3B6F1 hybrid mice, we asked whether they are a general feature of DR, independent of
genetic background.
We therefore compared two recently published datasets comprising whole-genome BS-seq
data of liver samples (S1 Table); one from DR fed female F1 hybrid mice (C3B6F1♀) and the
other from genetically heterogeneous DR fed female UM-HET3 mice (UM-HET3♀), and their
ad libitum (AL) fed controls [49,50]. UM-HET3 mice are employed by the National Institute
of Aging intervention testing program, thus representing a robust context to investigate lon-
gevity-related phenotypes [53]. DR increases the median lifespan of C3B6F1♀ from 902 to
1087 days (~ +25%) [49] and the mean lifespan of UM-HET3♀ mice from app. 836 to 1179
days (~ +39%; values for median lifespan were unavailable) [54]. The two datasets were gener-
ated from cohorts housed at different locations, undergoing DR from early adulthood on (DR
starting at 3 and 2 months, respectively). Mice from the two studies received food of differing
composition and were sacrificed at slightly different late ages (26 and 22 months, respectively)
[49,50]. Furthermore, sample extraction and sequencing were conducted at different facilities
and with differing sequencing conditions. Hence, a mixture of biological, experimental and
technical confounding factors differed between the two DR datasets. Given the relatively low
hepatic levels of non-CpG methylation, we centered our analysis on CpG methylation only.
The two datasets were pre-processed and analyzed in parallel, using an unbiased and conserva-
tive quantification approach as described in [49] (for details see “Methods”). In brief, we
binned the methylome using flexible-size windows covering 50 CpGs each, and overlapping
adjacent windows by 25 CpGs. Focusing on methylation profiles of both DR fed C3B6F1♀ and
UM-HET3♀ mice together with their respective controls, the total of four treatment groups
(Fig 1A) yielded a set of 931,702 bins with a median bin size of 4 Kbp, covering 23 million
CpGs in total. For each bin we calculated a single methylation value averaged across CpGs,
ranging from 0 to 100% (unmethylated to fully methylated).
In both strains, DR significantly altered methylation levels of specific bins in comparison to
corresponding age-matched controls (adjusted p< 0.05, Chi-squared test; minimal required
difference cutoff of 10%), thus overcoming the need for further SNP allele frequency correc-
tion. In total, DR induced 1,729 differentially methylated regions (DMRs) in C3B6F1♀ and
2,714 DMRs in UM-HET3♀ mice (Fig 1B; S2 Table). About 75% of DR-related DMRs were
hypermethylated, indicating a similar net effect of DR in each strain. Approximately 16% of
DR-related DMRs detected in C3B6F1♀ mice showed a significant overlap with DR-related
DMRs in UM-HET3♀ (p< 0.001, one-sided Fisher’s exact test), thus confirming a similar epi-
genetic remodeling independent of genetic background or experimental conditions (Fig 1C–
1E). Interestingly, the overlap between hypermethylated DMRs (19%) was clearly larger than
DNA methylation and lifespan-extending interventions
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Fig 1. Dietary restriction-related methylation changes are conserved across mouse strains. (A) Schematic representation of the data sets
analysed and comparisons made. We probed for Dietary Restricted (DR)-related DMRs at old age in B6C3F1 and UM-HET3♀mice to test
their conservation across mouse strains. Pre-processing was conducted in parallel for all experimental groups (B) Number of DMRs
(p<0.05, ±10%<DNA methylation difference) between each DR cohort and its respective control. Proportion of hypermethylated DMRs
are indicated in %. (C) Scatterplot comparison of bin-wise differences between DR-related DMRs in C3B6F1♀mice versus changes in the
DNA methylation and lifespan-extending interventions
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between hypomethylated DMRs (6%), suggesting that DR robustly alters the epigenome by
locally increasing DNA methylation (Fig 1D and 1E). These common DR-related DMRs
affected particularly key genes involved in lipid metabolism (Fig 1C and 1F; S3 Table).
The overlap between strains further increased (30% overlap) when comparing genes instead
of individual DMRs (for details see “Methods”), suggesting differential methylation of entire
gene loci as a conserved feature of DR (Fig 1G–1I). Indeed, DR induced similar differential
methylation profiles over fatty acid synthesis genes in both genetic backgrounds, including
Elovl6, Scd1 and Fasn [55] (S4 Table), stretching over both introns and exons but not the pro-
moter region or neighboring genes (Fig 1J–1L). Thus, targeted epigenetic reprogramming of
lipogenic genes in the liver is a robust feature of DR independent of genetic background.
Epigenetic remodeling under dietary restriction is tissue-specific
In order to assess if DR would remodel the methylome similarly in other tissues, we profiled
previously published reduced-representation bisulfite-seq (RRBS-seq) data from blood of DR
fed male F1 hybrid mice (B6D2F1♂) and DR fed male inbred mice (C57BL/6♂) [48] (S1A
Fig). B6D2F1 mice were generated by crossing C57BL/6 with DBA/2J animals [48], thus have
considerable genetic similarity with C57BL/6 mice. RRBS-seq allows differential analysis of
individual CpGs due to higher read coverage per cytosine and lessened filtering by multiple
testing correction [56,57]. In contrast to the liver, the majority of differentially methylated
CpGs (dCpGs) showed significant hypomethylation in response to DR (S1B Fig). The effects
of DR on DNA methylation in blood were well-conserved across strains, with 19 (hypermethy-
lation) to 40% (hypomethylation) common dCpGs in both strains (S1C Fig), which is in line
with previous studies [58]. We finally compared differentially methylated genes (for details,
see “Methods”) in both tissues and found substantial conservation across strains but no consis-
tent overlap across tissues (S1D and S1E Fig). Even though the discrepancy between blood and
liver may be in part explained by the different BS-seq techniques, our analysis indicates that
DR induces robust and highly tissue-specific epigenetic programs.
Dietary restriction, reduced growth factor signaling and rapamycin
treatment induced overlapping patterns of DNA methylation
Given the robust conservation of DR-related epigenetic reprogramming, we asked whether
other longevity interventions also remodelled DNA methylation specifically (Fig 2A). We pro-
filed the hepatic methylomes of female DR C3B6F1♀ mice, male Ames dwarf mice from a
closed colony (strain referred to as Prop1♂) and rapamycin treated UM-HET3♀ mice, all
relative to age-matched controls (Fig 2B) [49,50]. Compared to their control group, Ames
dwarf mice show an almost 50% increase in mean lifespan (controls: 723 days; Ames dwarfs:
1076 days; values for median lifespan were unavailable) [25], while the median lifespan of
same bin in dietary restricted UM-HET3♀. Bins overlapping the genes Elovl6, Acly, Scd1 and Irs2 are highlighted. Methylation differences in
dietary restricted C3B6F1♀mice were significantly associated with differences in dietary restricted UM-HET3♀mice (One-sided Fisher’s
exact test p<0.001). Number of bins in each quadrant is indicated in blue. (D, E) Venn diagrams depicting the overlap of significantly hypo-
(D) and hypermethylated (E) DMRs in both DR cohorts. Proportions of overlap relative to the DR (C3B6F1♀) set are indicated in % (p-
values; ��� p<0.001, �� p<0.01, � p<0.05, Fisher’s exact test). (F) Functional enrichment of differentially methylated genes (with� 2
common DMRs overlapping) detected in both DR cohorts (n = 51) (G, H) Venn diagrams depicting the overlap of significantly hypo- (G)
and hypermethylated (H) genes (� 2 DMRs per cohort overlapping) present in both DR cohorts. Proportions of overlap relative to the DR
(C3B6F1♀) set are indicated in % (p-values; ��� p<0.001, �� p<0.01, � p<0.05, Fisher’s exact test). (I) Functional enrichment of differentially
methylated genes (� 2 DMRs per cohort overlapping) detected in both DR cohorts (n = 71) (J-L) Differential methylation landscape of the
Elovl6, Egf (J), Scd1 (K) and Fasn (L) gene loci in both DR cohorts. The methylation increase upstream of Scd1 did no pass statistical testing.
Bins are represented as bars with color scale and height indicating methylation differences. Arrows indicate gene orientation; merged mRNA
structure is depicted below.
https://doi.org/10.1371/journal.pgen.1007766.g001
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Fig 2. Cross-strain hepatic DNA methylation changes in response to longevity interventions. (A) Schematic of
treatment comparisons: Various longevity interventions act on DNA methylation through retardation of ageing. We
explored direct longevity-related (green arrow) effects on DNA methylation. (B) Schematic representation of the data
sets analyzed and comparisons made. We probed for intervention-related DMRs at old age by comparing long-lived
mice to their respective controls. Pre-processing was conducted for all shown treatment groups (C) Boxplot
DNA methylation and lifespan-extending interventions
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UM-HET3♀ mice increases by ~26% in response to daily doses of 42 ppm rapamycin (con-
trols: 896 days; rapamycin-treated: 1132 days) [59]. For DR, we included only C3B6F1♀ mice,
given that WGBS-seq and RNA-seq data for both young and old mice were available only for
this strain, and were required for downstream analyses (see below). With six treatment groups,
our binning approach yielded a set of 922,788 bins covering 23 million CpGs with a median
bin size of around 4 Kbp. Genome-wide levels of DNA methylation were largely unaffected by
intervention or strain, with most bins showing levels in the range of 70–90% (Fig 2C).
In total, 15,075 DMRs showed significant methylation change in at least one intervention
(intervention-related DMRs), which represents less than 1.5% of the entire methylome. Of
these, DR induced 1,619 DMRs, rapamycin 1,415 and genetic dwarfism 12,619 (S5 Table).
Both non-genetic interventions thus had a weaker impact on the epigenome than genetically
reduced somatotropic signaling (Fig 2D and 2E). Both DR and dwarfism caused predomi-
nantly gains in DNA methylation, whilst rapamycin treatment induced equal amounts of
hyper- and hypomethylated DMRs (Fig 2D and 2E). Remarkably, 412 hypermethylated DR-
related DMRs (33%), and 133 hypermethylated rapamycin-related DMRs (17%) were also
detected in Ames dwarf mice (Fig 2F). In addition, 9 hypermethylated DMRs were common
among all three interventions. Given that the global methylome remained unchanged, these
overlaps were highly significant (each: p< e-16, Fisher’s exact test), strongly indicating that
their co-occurrence was not due to chance. In clear contrast, we did not detect any hypo-
methylated DMRs common to all three interventions and only few hypomethylated DMRs
between any two interventions, for which we found no convincing functional association
(Fig 2G).
The relatively small overlap of hypermethylated DMRs between DR and rapamycin-treated
mice could partly result from low read coverage, which reduces the statistical power. To evalu-
ate this possibility, we conducted a less constrained analysis and asked whether significant DR-
related DMRs would associate with methylation changes in Ames dwarf or rapamycin treated
mice, independent of their statistical significance (for details see “Methods”). DR-related
DMRs associated with methylation changes in Ames dwarf (p< 0.001, one-sided Fisher’s
exact test) but not in rapamycin-treated mice (Fig 3A and 3B), confirming our earlier result.
Finally, we considered that the relative large absolute bin size (~ 4 Kbp) might reduce the
detectability of common methylation patterns and thus repeated the binning and differential
methylation analysis with bins covering only 20 CpGs (2.3 mio. bins; median size: 1.49 Kbp)
and 10 CpGs (4.6 mio. bins; median size: 649 bp) (S2A Fig). Consistent with the 50-CpG bin-
ning, the majority of DMRs under DR feeding and in Ames dwarf mice tended to be hyper-
methylated, and genetic dwarfism caused more DMRs than DR or rapamycin treatment (S2B
Fig). Reducing the number of CpGs per bin increased the overall noise between long-lived and
control animals (S2C Fig), yet the overlaps among the hypermethylated DMRs remained
largely consistent (S3A Fig) and common 10-CpG-DMRs mapped to the same regions
detected with 50-CpG bins (S3B Fig). Remarkably, we did not detect any hypomethylated
DMRs common to all three interventions, thus validating our previous findings (S3C Fig).
representation of global DNA methylation levels in the liver of aged DR, Ames Dwarf and Rapamycin treated mice
next to their respective controls. Strain and sex are indicated above. (D) Number of significantly differentially
methylated regions (DMRs) (p<0.05, ±10%<DNA methylation difference) between each longevity intervention and
it’s respective control. Proportion of hypermethylated DMRs are indicated in %. (E) Scatterplot representation of
methylation values of each bin in control and long-lived animals. Intervention-related DNA methylation changes are
highlighted. Bins that were not differentially regulated (background) are represented in grey. Data density is indicated
by color code. (F, G) Venn diagram depicting the overlap of significantly hyper- (F) and hypomethylated (G) DMRs
under DR, Dwarfism and rapamycin treatment relative to the control groups at old age (p-values; ��� p<0.001, ��
p<0.01, � p<0.05, Fisher’s exact test).
https://doi.org/10.1371/journal.pgen.1007766.g002
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Fig 3. Conserved intervention-related remodeling of gene body methylation. (A, B) Scatterplot comparison of bin-wise methylation
differences between DR-related DMRs versus changes in the same bins in Ames dwarf (A) and rapamycin-treated (B) mice, respectively.
Bins overlapping the Elovl6 gene are highlighted in red. Methylation differences under DR were significantly positively associated with
differences in Dwarfs (One-sided Fisher’s exact test p<0.001) but not with rapamycin-treated mice. Number of bins in each quadrant is
indicated in blue. (C) Enrichment analysis of common hypermethylated DMRs between DR and Dwarfs (n = 403) and rapamycin
DNA methylation and lifespan-extending interventions
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Taken together, reduced growth factor signaling and reduced TOR signaling induce DNA
methylation signatures in distinct regions of the genome, pointing to a similar epigenetic
remodeling as identified before under DR. In addition, several hundred hyper- but not hypo-
methylated DMRs are common to at least two interventions, indicating a partly conserved epi-
genetic signature across interventions, mouse strains and sexes.
Ames Dwarf mice share functionally distinct gene body methylation
patterns with rapamycin-treated and dietary restricted mice
Following our findings from DR-related hypermethylation of lipid metabolism genes, the
overlapping hypermethylation signatures among interventions could suggest a partially shared
epigenetic program, acting on specific, functionally connected regions of the genome. In line
with our hypothesis, hypermethylated DMRs shared between Ames dwarf and either DR or
rapamycin treatment were strongly enriched over gene bodies and open/active chromatin,
confirming coordinated methylation increase over euchromatic, coding regions of the genome
(Fig 3C; Chromatin segmentation data from the ENCODE project [60]). To assess if specific
functional elements within genes were particularly associated with intervention-related meth-
ylation changes, we repeated the enrichment analysis using the 10-CpG-DMRs (S4A–S4C Fig)
for improved resolution. We found equal enrichment of common intervention-related DMRs
over exons, intron and exon/intron-boundaries, thus confirming that these hypermethylation
patterns tend to equally affect each part of the gene body (S4D Fig). Using annotation from the
ENCODE and Cistrome platforms [61], we also confirmed a strong enrichment of binding
sites of several transcription factors and DNA-binding proteins (S4B and S4C Fig).
As described before [49], hypermethylated genes under DR were functionally enriched for
fatty acid metabolism and regulation of lipogenesis (S5A Fig; S6 Table). In contrast, rapamycin
treatment caused hypermethylation primarily over genes involved in carbohydrate and amino
acid metabolism, and several cell proliferation and growth factor receptor genes (S5B Fig),
including mediators of TGF-β signaling (Acvr2b [62] Ltbp1, Ltbp4 [63]) and the growth hor-
mone receptor Ghr (S5B Fig; S7 Table). Differentially methylated genes in Ames dwarf mice
exhibited the strongest functional association, with enrichment for lipid synthesis, amino acid
metabolism, wound healing, cellular differentiation and growth factor binding (S5C Fig; S8
Table). Genetic dwarfism thus appeared to cause hypermethylation over similar pathways as
observed under DR- and rapamycin-treatment separately.
We therefore analyzed the functional association of genes that were hypermethylated in at
least two interventions (� 2 overlapping DMRs per intervention). Indeed, Ames dwarf mice
shared hypermethylation patterns over lipid metabolism genes with DR fed mice (Fig 3D and
3E; S10 Table), while also showing hypermethylation of cell proliferation and growth factor
signaling genes similar to rapamycin-treated mice (Fig 3D and 3F; S11 Table). As exemplified
by Elovl6 and Ghr (Fig 3G and 3H, S4D Fig), DNA methylation was altered over larger regions
of the gene body, similar to findings in both DR cohorts (Fig 1J–1K). In summary, the non-
genetic interventions DR and rapamycin treatment thus resemble different components of the
epigenetic program induced by genetic dwarfism. Interestingly, dwarfism reduces expression
treatment and Ames dwarf mice (n = 124) over genomic and ENCODE chromatin segmentation. Bars indicate the ratio of the observed
DMR frequency and the average frequency across the genome (log2-transformed; adjusted p-values; ��� p<0.001, �� p<0.01, � p<0.05,
Fisher’s exact test). (D) Venn diagram depicting the overlap of hypermethylated genes (� 2 DMRs overlapping) under DR, dwarfism and
rapamycin treatment (p-values; ��� p<0.001, �� p<0.01, � p<0.05, Fisher’s exact test). (E, F) Functional enrichment of common
hypermethylated genes between Ames dwarf mice and DR (E; n = 101) or rapamycin-treatmed mice (F; n = 58). (G,H) Differential
methylation landscape of the Elovl6 (G) and Ghr (H) gene loci. Bins are represented as bars with color scale and height indicating
methylation differences. Arrows indicate gene orientation; merged mRNA structure is depicted below.
https://doi.org/10.1371/journal.pgen.1007766.g003
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of genes involved in hepatic lipogenesis [64,65] and alters expression of genes involved in
growth factor signaling and cell proliferation [64,66], thus paralleling the observed methylation
signatures.
Hypermethylation patterns associated with longevity-extension are not
explained by retardation of ageing alone
DR, rapamycin treatment and reduced somatotropic signaling slow down age-related changes
of the methylome [47–50,52,67]. The common hypermethylation patterns described here were
analyzed in old animals and could thus result from protection of specific genes against age-
related methylation changes. Alternatively, common hypermethylation DMRs may have
formed by an active reprogramming that is partly unrelated to ageing. To assess whether lon-
gevity intervention-related DMRs resulted solely from delayed ageing, we first profiled age-
related changes in wild type, normally fed, non-drug-treated members of each of the three
mouse strains (S6A Fig). Pre-processing and binning based on young and old control samples
across strains yielded 859,750 bins, showing globally only mild age-related changes (S6B Fig).
Ageing induced only 3,349 and 3,133 DMRs in C3B6F1♀ and UM-HET3♀ mice, respectively,
but over 8,500 significant changes in the genetic background of the Prop1♂ strain, suggesting
a strong interaction between genotype and age on DNA methylation (S6C Fig; S12 Table).
Age-related DMRs in the genetic background of the Prop1♂ mice furthermore showed a bias
towards age-related hypomethylation (S6C and S6D Fig), which was not observed in the other
two wild type mouse strains. In order to minimize these strain-specific biases, we selected age-
related DMRs present in at least two strains (S6E and S6F Fig) as reference for a comparison
with intervention-related DMRs. Strikingly, 282 of 545 (53%) intervention-related, hyper-
methylation DMRs (found in at least two interventions) were not hypomethylated during age-
ing (S7A Fig; S5 Table). This result suggests that intervention-related methylation changes
were not solely a consequence of general protection against ageing-related changes in the epi-
genome and instead reflect a specific feature of longevity interventions.
Intervention-related DNA methylation is rapidly induced at young age
We next determined whether intervention-related methylation changes were already detect-
able at young age. We analyzed DNA methylation of young DR-treated C3B6F1♀ (5 months)
and Ames dwarf mice (2 months) in comparison to their respective controls (S3B; data for
young rapamycin- or DR-treated UM-HET3♀ mice were unavailable). Our binning approach
yielded 1,018,051 bins covering 25.5 million CpGs. Differential methylation analysis detected
1,944 DR- and 5,547 dwarfism-related DMRs at young age (S13 Table), with similar hyper-to-
hypomethylation ratios as observed in old animals (compare Fig 2D, S7C Fig). DR- and dwarf-
ism-induced methylation changes at young age were also significantly associated with each
other, confirming common epigenetic patterns already at this age (S7D Fig). Strikingly, inter-
vention-related, hypermethylated DMRs in young animals were significantly enriched over
intervention-related DMRs that were also detected at old age. Reprogramming of the epigen-
ome in response to DR and reduced somatotropic signaling is thus induced in young adult ani-
mals, prior to age-related methylation changes (S7E Fig).
We further asked if intervention-related DNA methylation patterns in young mice also
affected the same genes as seen at old age and found a weak but significant overlap (12%)
between young and old DR fed mice (S7F and S7G Fig), including lipid metabolism genes
Elovl6, Scd1 (S7H and S7I Fig) and Pnpla3. The epigenetic reprogramming under DR is thus
induced early in adulthood, but becomes more pronounced during chronic long-term treat-
ment. In contrast, the set of common hypermethylated genes between young and old Ames
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dwarf mice covered over 650 genes (69% overlap), revealing that the extensive epigenetic
reprogramming in response to reduced somatotropic signaling occurs early in life and is main-
tained life-long (S7G Fig). DR and reduced somatotropic signaling thus remodel the epigen-
ome before age-related changes occur, additionally confirming that hypermethylated patterns
detected in long-lived mice cannot solely result from deceleration of ageing.
Joint BS-seq profiling identifies candidate marker regions of longevity
While reliable DNA methylation markers (‘epigenetic clocks’) for murine ageing have been
previously developed, including local markers like Elovl2, a specific epigenetic biomarker pre-
dicting interventions that will ameliorate ageing in mice does not exist [46–48,68]. Such a
marker would probe immediately for responsiveness to interventions, instead of wait for the
delay of age-related effects. The WGBS-seq profiles analyzed here comprised three different
interventions in different genetic backgrounds, thus representing a suitable dataset to investi-
gate the general feasibility of an intervention-related marker. We found nine hypermethylated
DMRs shared among all three longevity interventions (see S7A Fig; S5 Table), as exemplified
by the Tat gene locus (S8A and S8B Fig). Of these, four hypermethylated DMRs did not over-
lap with age-related hypomethylation (S7A Fig; S5 Table) making them suitable marker candi-
dates to probe for longevity-intervention-specific effects. DNA methylation levels of individual
cytosines present within the four DMRs increased in concert in all three longevity interven-
tions (p<0.001, Paired Wilcoxon rank-sum test) (S8C Fig). We independently tested the puta-
tive marker regions in DR-treated UM-HET3 mice, which were not used to identify these
regions previously, and found the expected hypermethylation pattern (p<0.001, Paired Wil-
coxon rank-sum test) (S8C Fig).
Next, we reduced the DMRs to four representative 500 bp regions that can be investigated
by PCR-based assays. We confirmed that hypermethylation of the 125 resulting cytosines was
still well correlated for all three interventions (S9A Fig; S14 Table). We also detected significant
hypermethylation of these cytosines in DR-treated UM-HET3 mice (S9A; p<0.001, Paired
Wilcoxon rank-sum test). The four regions were selected to not overlap with age-related
changes in DNA methylation (S7A Fig) and accordingly, we did not observe consistent meth-
ylation changes with age for the representative 500 bp regions (S9B Fig).
We asked if the putative marker regions would be able to predict extended lifespan when
analysed in young DR or Ames dwarf mice. Indeed, young Ames dwarf mice showed signifi-
cant hypermethylation over the marker cytosines, indicating that reduced somatotropic signal-
ing during development primes for an extended lifespan (S9C Fig). Our marker readout is
thus in agreement with analyses of the epigenetic clock in young Ames dwarf mice, which is
already significantly decelerated at 2 months of age [47]. Surprisingly, however, young DR fed
C3B6F1♀ mice (3 months ad libitum feeding followed by 2 months DR) showed no significant
difference over the marker regions. The marker thus indicates that 2 months of DR feeding at
young age do not suffice to extend lifespan later on (S9C Fig). Indeed, recent studies in rats
confirmed that DR feeding limited to two to six months of age does not cause an extension of
lifespan later on [12]. This result is also consistent with findings from DNA methylation
clocks, where long-term, but not short-term DR, resulted in a significant reduction of DNA
methylation age [48]. In addition, we tested whether the marker regions could also be used in
other tissues and analysed the RRBS-seq data from blood of DR fed B6D2F1♂ mice (see S1
Fig). Only half of the 125 CpGs were covered by RRBS-seq and the corresponding methylation
levels in blood of control animals did not match the observed levels in the liver (compare S9A
and S9D Fig). However, despite the low coverage there was no evidence for a predictive func-
tion of this marker region in the blood.
DNA methylation and lifespan-extending interventions
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007766 November 21, 2018 12 / 37
In order to verify our marker experimentally, we measured DNA methylation at the marker
regions in five DR and five AL fed C3B6F1♀ mice (24 months of age) from an independent
batch of animals using targeted Bisulfite Amplicon sequencing (BS-AS; for details see “Meth-
ods”) [69]. To test if the marker would probe successfully for other lifespan-extending inter-
ventions, we also performed BS-AS in four female C3B6F1 mice genetically deficient for Irs1
(Irs1KO; 24 months of age) [70] and four controls. The BS-AS assay measured DNA methyla-
tion levels at 80 CpGs, thus covering most of the CpGs within the marker regions (S10A Fig).
Unsupervised hierarchical clustering of methylation levels at these 80 CpGs separated most of
the samples into controls and long-lived mice, indicating that DNA methylation at these sites
can classify for extended lifespan (S10B Fig). Averaged methylation levels across all replicates
clustered similarly, confirming that they are not biased by single outlier replicates (S10B Fig).
Remarkably, we detected a significant concerted hypermethylation at these CpGs both in DR
fed and Irs1KO mice (S10C; p<0.05, Paired Wilcoxon rank-sum test). Consistently, we found
18 hypermethylated dCpGs under DR feeding and 32 dCpGs in Irs1KO mice (4 and 12 hypo-
methylated dCpGs, respectively). One of the four marker regions, however, appeared to be
false positive in the WGBS-seq data, as most long-lived animals showed no consistent change
at these CpGs (S10B Fig). Excluding the corresponding CpGs improved the result of the detec-
tion of concerted hypermethylation (S10D; p<0.05, Paired Wilcoxon rank-sum test).
In summary, concerted hypermethylation of these marker cytosines in liver correlates spe-
cifically with longevity upon DR, reduced TOR and reduced growth factor signaling. By testing
the marker cytosines in an independent model of longevity, we demonstrate the feasibility of
developing novel epigenetic markers that can probe specifically for intervention outcome.
Epigenetic reprogramming parallels transcriptional repression of growth
factor signaling networks in Ames dwarf mice
Gene body hypermethylation under DR has been associated with transcriptional repression
of lipogenesis, pointing to a tight coupling between DR-related remodeling of the epigenome
and gene expression [49]. We asked if expression and differential methylation would also be
inversely associated in Ames dwarf mice, given their similar epigenetic patterns to DR-treated
mice. Focusing on genes with at least 2 dwarfism-related DMRs mapping to the gene body, we
plotted methylation differences against expression changes (Fig 4A; S15 Table). As previously
described for DR [49], the expression of hypermethylated genes tended towards down-regula-
tion in Ames dwarf mice (p< 0.001, Binomial test) and this was even more pronounced when
considering only significantly differentially expressed genes (Fig 4A; S15 Table). We also
found this inverse correlation to be present in young Ames dwarf mice (S10A Fig; S16 Table),
suggesting this association to be early-onset and maintained life-long. Correspondingly, we
found at young and old age similar functional enrichments of GO terms and Reactome path-
ways, including Unfolded Protein Response (UPR), lipid metabolism and wound healing (Fig
4B, S10B Fig; S16, S17 and S18 Tables). In addition, we found strong dwarfism-related hyper-
methylation and repression of several growth factor signaling and cell survival genes (Fig 4B–
4D, S10B and S10C Fig; S16, S17 and S18 Tables). Notably, this included the growth hormone
receptor (Ghr, Fig 3H) and several direct and indirect downstream targets, such as the systemic
growth mediator Igf-1 [71] and the hepatoprotective genes Egfr, Lifr and Onecut1 (Hnf-6) [72–
78]. These regulators of cell survival and growth carry out key functions in liver regeneration
and also play major roles in promoting cancer onset and progression [79–87].
Whilst increased DNA methylation in gene bodies is typically correlated with increased
expression [88], recent studies also demonstrated an inverse association [89–91]. For instance,
the strongest inverse association between DNA methylation and expression in humans was
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Fig 4. DNA methylation differences in Ames dwarf mice predict expression changes. (A) Scatterplot of expression differences versus
methylation differences of dwarfism-related DMRs. Dashed lines indicate DNA methylation cutoff of> ±10%. DNA hypermethylation
associated significantly with reduced gene expression (Binomial test p< 0.001). Number of differentially methylated genes in each
quadrant is indicated in blue and red, for all genes and differentially expressed genes, respectively. (B) Gene ontology and Reactome
enrichment of genes with a negative correlation of gene expression and methylation. Lengths of bars represent negative ln-transformed,
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previously found in so-called undefined intragenic DMRs (uiDMRs), which locate 0.3–8 Kbp
downstream of the promoter. [89]. In line with these findings, we observed an enrichment of
intervention-related methylation changes at uiDMRs (Fig 3C and S4A Fig). Moreover, the sig-
nificant inverse association between dwarfism-related changes in methylation and expression
remained consistent when restricting the analysis to uiDMRs (S10D and S10E Fig). Differen-
tial methylation over uiDMRs may thus be a putative mechanism mediating the transcriptional
consequences of the epigenetic reprogramming.
In summary, our results thus reveal strong epigenetic and transcriptional silencing of the
growth hormone signaling axis, which may contribute to delayed occurrence of neoplastic dis-
eases in Ames dwarf and growth hormone signaling deficient mice [9,29,30].
Dwarfism and DR remodel methylation and expression of Fgfr3
Given the common epigenetic signatures occurring across longevity interventions (Fig 2E
and 2F), we asked whether methylation and transcriptional changes would also be common
between DR fed and Ames dwarf mice (RNA-seq data for rapamycin-treated mice were not
available). In line with previous work [49], we found hypermethylation and transcriptional
repression of lipogenesis genes to be significantly associated in DR fed mice (p< 0.05, Bino-
mial test; S11A and S11B Fig; S19 and S20 Tables). DR and Ames dwarf mice showed similar
transcriptional patterns, with an overlap of 421 commonly regulated genes (S11C and S11D
Fig). Surprisingly, the overlap between commonly hypermethylated and significantly
repressed genes comprised only a non-significant set of five genes, suggesting that DNA
methylation and transcription are differently coupled under DR and reduced somatotropic
signaling (S11E Fig). Interestingly, however, fibroblast growth factor receptor 3 (Fgfr3,
S11F–S11H Fig), a key mediator of mitogenic signals and known activator of both the Ras-
Mapk and PI3K-AKT pathways [92], was found to be hypermethylated and repressed in DR
and Ames dwarf mice.
As a crucial regulator of cell growth and survival, Fgfr3 is frequently up-regulated in various
cancers including hepatocellular carcinoma [93–96]. Hepatic Fgfr3 is also repressed in mouse
models of genomic instability, which exhibit dwarfism and GH-IGF1-signaling deficiency,
thus paralleling our findings in Ames dwarf mice [97,98]. Hence, the anti-tumorigenic effects
of DR and dwarfism [9,29] may involve repression of Fgfr3. Furthermore, in-vitro studies with
bladder cancer cell lines confirmed Fgfr3 as a direct activator of lipogenesis via Srebf1 [99–
101], which itself becomes hypermethylated and repressed under DR [49,102,103]. Remark-
ably, gene expression changes induced by knockdown of Fgfr3 in RT112 cells [100] overlapped
significantly with expression changes observed in livers of DR fed C3B6F1♀ mice (S12A–S12C
Fig; S21 Table) including down-regulation of various hypermethylated lipogenesis genes (S22
Table). Our analysis thus point to a role of Fgfr3 in mediating the effects of DR and genetic
dwarfism in the liver.
adjusted pvalues using Fisher’s exact test. Cells indicate log2-foldchanges (log2FC) between Ames dwarf and control group per gene. (C)
Differential methylation landscape of the Egfr gene locus at young and old age. Bins are represented as bars with color scale and height
indicating methylation differences. Arrows indicate gene orientation; merged mRNA structure is depicted below. (D) Egfr mRNA
expression by RNA-sequencing in control and Ames dwarf mice at young and old age, respectively (n = 4 vs 2 and 4 vs 4). (E) Schematic
outline of differential methylation and gene expression along the Hypothalamic–pituitary–somatotropic axis in Ames dwarf mice: In Ames
dwarf mice, the release of Growth Hormone (GH) is impaired. The corresponding Growth hormone receptor (Ghr) shows respective
transcriptional downreguation in the liver. Direct (solid arrows) and indirect (dashed arrows) downstream targets of GHR signaling, show
elevated methylation levels and corresponding transcriptional repression. Further hypermethylated/downregulated targets include the
hepatoprotective factors Egfr, Lifr and Onecut1, involved liver growth regulation, cell survival and metabolism.
https://doi.org/10.1371/journal.pgen.1007766.g004
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Discussion
Physiological consequences of DR including lifespan extension are strongly dependent on
genetic background, sex and protocol [10,22,104]. After detecting epigenetic reprogramming
of lipid metabolism in response to DR in an earlier study [49], we aimed to determine the
robustness of these DNA methylation changes in a different genetic background. We further
investigated the extent to which the epigenome is also remodeled in response to other longev-
ity-extending interventions. We hypothesized that this epigenetic remodeling might occur
independently of decelerated ageing effects. In this case, intervention-related methylation pat-
terns would (I) show a pattern distinct from age-related methylation changes and (II) already
be detectable in young animals, i.e., before age-related changes can occur. Given that epige-
netic modifications mediate long-term consequences for gene expression [40,105], remodeling
of the methylome could causally contribute to improved health at old age and increased life-
span. We therefore investigated a possible association between intervention-related methyla-
tion and gene expression.
The net effect of DR on the methylome was highly comparable between strains and studies.
Interestingly, the total number of DR-related DMRs in UM-HET3♀ mice was about 56%
higher compared to C3B6F1♀ mice, which correlates with the ~56% stronger improvement
in lifespan in the genetically heterogeneous strain (+39% in UM-HET3♀ and +25% in
C3B6F1♀mice, relative to control). This may hint towards an association between the extent of
the epigenetic reprogramming and the improvement in lifespan. However, when comparing
which specific regions were affected, approximately 80% of DR-related, hypermethylated
DMRs and 95% of hypomethylated DMRs were only detected in one mouse strain/dataset.
While these differences may be, in part, due to the genetic background and differing sequenc-
ing protocols [106], there were other confounding factors between the studies. For instance,
the food composition differed between both DR experiments, which is known to affect meta-
bolic outcomes of DR [24]. This may in turn affect the DR-induced epigenetic changes, and
consequently the comparability between the two strains. Consistently, we observed a stronger
cross-strain conservation of methylation patterns in blood of closely related, DR-fed mouse
strains from the same study, i.e. that were housed at the same animal facility and undergoing
identical sample preparation/sequencing [48]. Given our conservative filtering, common
DMRs in the liver may thus not reach statistical significance in two separate datasets. In this
context, the 20% overlap of hypermethylated DMRs represents a remarkably robust core set of
DR-related DMRs.
Hepatic mRNA expression changes between two commonly housed, DR-fed mouse strains
showed a 50% overlap in their response to DR [10], indicating that DR induced gene expres-
sion changes might be better conserved between mouse strains than epigenetic changes. Inter-
estingly, this and other studies identified suppression of hepatic lipogenesis as one of the most
conserved transcriptional signatures of DR in rodents [10,49,102,103,107], which parallels the
conserved hypermethylation events affecting direct targets of the lipogenic transcription factor
Srebf1, including Fasn, Acly, Me1, Elovl6 and Scd1 [55,108–112]. Our findings thus link core
DR-related expression patterns with their directed epigenetic reprogramming over time.
Our analysis extended the concept of intervention-related DNA methylation changes to
both reduced TOR and somatotropic signaling. We also found here that the intervention with
the strongest improvement in lifespan (dwarfism) induced the most DMRs, while rapamycin
and DR, which have similar effects on lifespan, induced comparable numbers of DMRs. How-
ever, the detection of significant methylation changes is dependent on various technical factors
such as coverage [106], and we can therefore not exclude that these correlating observations
are rather coincidental.
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Hypomethylated DMRs were only shared to a minor extent among interventions, and we
found no convincing functional association. Hypomethylated DMRs could thus represent
treatment-specific changes. In contrast, intervention-related, hypermethylated DMRs were
commonly targeted to gene bodies and partly shared among interventions. Interestingly,
downstream mediators of the key longevity pathways, PI3K/Akt (Gsk3β) and Raf signaling
(Erk1/2) [1,2,113,114], regulate de-novo methyltransferase 3b (Dnmt3b) [115], which may be
explored as potential mechanism driving the formation of common hypermethylation pat-
terns. Around 65% (DR) to 95% (Ames dwarf mice) of hypermethylated DMRs were only
found in one intervention. However, given the results from the cross-strain comparison of
DR-related effects, about 80% of non-common DMRs can be expected by differences in
genetic background and technical variation alone. Sex differences in patterns of DNA methyla-
tion [116,117] may further reduce the comparability between epigenomes. We cannot yet test
directly for the importance of these experimental factors in a meta-analysis, but presumably
the set of common DMRs would have been greater if all the experiments had been conducted
with identical conditions and protocols.
Notwithstanding, methylation over four regions robustly increased in response to all three
interventions independent of strain and sex, while showing no age-related changes, thus meet-
ing the main requirements for a putative epigenetic marker to directly assess the response to
lifespan-extending interventions. As such, we could experimentally confirm the validity of our
marker in an independent batch of mice and successfully probe for longevity in Irs1KO mice
that were not involved in the marker selection. Albeit weak in effect, methylation at the CpGs
measured by targeted BS-AS was overall sensitive enough to detect the anticipated, significant
difference. Epigenetic clocks [42,46–48] and methylation-based biomarkers of biological age
[68,118] measure the ‘ticking rate’ of ageing and can therefore probe only for the indirect
deceleration by longevity interventions. In addition, mouse epigenetic clocks currently rely on
sufficient coverage of all clock-CpGs by RRBS-seq and show error rates of up to ± 4 months
[47,48], which limits assessment of short-term effects.
In contrast, concerted hypermethylation over just these four regions was reliably correlated
with longevity intervention outcome. None of the clock-CpGs mapped within the four inter-
vention-related DMRs [46–48], unsurprising since clock-CpGs were selected to probe ageing.
In addition, one of the four DMRs mapped to the Tat gene locus, which has been previously
shown to be unaffected by age-related changes in DNA methylation in rat liver, spleen and
brain [119]. The putative marker regions thus seem truly sensitive to intervention- but not
age-related effects. We found no obvious functional association between the DMRs, of which
two mapped over genes (Exon of Tat; intronic CGI of Foxp4) and two at intergenic regions,
suggesting that methylation markers are not directly linked to a distinct cellular process
[42,46–48]. The marker regions presented here could be easily analyzed in published WGBS-
seq datasets or directly assessed by with our BS-AS protocol, thereby reducing costs and exper-
imental effort.
Our findings act as a proof-of-principle to demonstrate the general feasibility of a treat-
ment-specific DNA methylation marker. Due to the limited number of available samples, the
marker DMRs yield only a binary output (statistically significant or non-significant hyper-
methylation). It will be interesting to test the corresponding methylation patterns in lifespan-
extending interventions that do not primarily target energy metabolism, e.g. aspirin treatment
[120] or ablation of senescent cells [121]. Finally, we show that the marker region appears to
be dependent on the tissue, which, in the case of the liver tissue used in this study, could only
be sampled by invasive techniques, and similar markers should be developed for blood or skin.
Future marker assays would allow defining the critical treatment length and timing for new
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longevity interventions to improve lifespan, and assess the sustainability of the effects once the
intervention is suspended.
In agreement with common signaling pathways associated with the three lifespan-extend-
ing interventions [15,18,19,34–37], we found that DR and rapamycin treatment resembled
functionally distinct epigenetic patterns of Ames dwarf mice. Metabolically, dwarfism protects
from hepatic insulin resistance, reduces high-fat diet induced liver steatosis and suppresses de-
novo lipogenesis genes including Elovl6, Acly and Fasn [64,122,123], thus indicating reduced
lipogenic activity through Srebf1 [108,124–126]. Snell dwarf mice, another mouse model of
reduced somatotropic signaling, also show age-independent down-regulation of Srebp1 and
several downstream targets in the liver [127]. Furthermore, DR fed mice and Snell/Ames
dwarf mice exhibit altered transcriptional dynamics of peroxisome proliferator-activated
receptor α (PPARα) [128], which in turn regulates Srebp1 activity [129,130] and may thus
explain the similar expression patterns of lipogenesis genes. Consistently, in both DR and
Ames dwarf mice we observed hypermethylation over several Srebf1-target genes (Elovl5,
Elovl6, Fasn, Gpam, Acly, Acaca, Aacs) [55,108,112,131–134]. Their hypermethylation was fur-
ther accompanied by transcriptional repression in Ames dwarf mice at young age, which was
also observed in young Snell dwarf mice [127]. Hence, a conserved epigenetic module links
metabolic reprogramming with increased protection against hepatic steatosis and insulin resis-
tance in Ames dwarf and DR mice. Rapamycin, in contrast, activates hepatic lipid metabolism
[135,136] and shares only a small subset of regulated transcripts with DR [137], which is in
line with hypomethylation of genes involved in lipid and fatty acid metabolism (compare S5A
and S5B Fig). These opposite methylation changes might also explain the higher number of
hypomethylated DMRs under rapamycin treatment and the weak overlap with DR.
Pharmacological suppression of mTOR affects cellular sensitivity to growth factors [138],
which also marks a fundamental consequence of genetic dwarfism [28]. Rapamycin represses
growth factor signaling during liver injury and fibrosis [66,139] and is tested in clinical trials
for the treatment of advanced hepatocellular carcinoma (HCC) [140], indicating a role in both
tissue regeneration and cancer. Consistently, hypermethylation of growth factor receptors/
mediators such as Lifr [78], Fgfr2 [141], Acvr2b [62], Ltbp4, Ltbp5 [63] and the Growth hor-
mone receptor (Ghr) suggests long-term adaptation of the epigenome to altered growth and
mTOR signaling, which was even more prevalent in Ames dwarf mice.
In Ames dwarf mice specifically, we show for the first time how reduced somatotropic sig-
naling is paralleled by potent hypermethylation and transcriptional repression of the Ghr-Igf1
axis and downstream target genes with key roles in tissue growth and regeneration [72–76].
These hepatoprotective mediators (Egfr, Lifr, Onecut1) [78] are also highly oncogenic
[72,73,78,79] and tight control of their expression could therefore contribute to the delayed
onset of neoplasia in Ames dwarf mice [29,30]. The age-ameliorating effects of dwarfism have
also been implicated in the prevention of cancer by maintaining a youthful epigenome [50],
which may work in tandem with the epigenetic reprogramming of mitogenic signaling
described here. Thus, Ames dwarf mice instigate an ample epigenetic silencing of growth hor-
mone-related signaling, which may also help to delay the onset of cancer.
The remarkably strong association between intervention-related shifts in DNA methyla-
tion, transcription and phenotype marks a key difference to age-related methylation changes,
where epigenome and gene expression changes are generally not correlated [49,50,142]. Age-
related changes also tend to affect predominantly promoter CGIs [46,49], while intervention-
related DMRs, which are not a result of delayed ageing alone, tend to map over intragenic ele-
ments. Given the strong link between robust intervention-induced expression [143,144] and
the gene body methylation patterns in long-term DR and Ames dwarf mice, it is thus tempting
to speculate about a direct relationship. As such, we have identified a strong inverse association
DNA methylation and lifespan-extending interventions
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007766 November 21, 2018 18 / 37
between hypermethylation at uiDMRs and mRNA expression, and elucidating a potentially
causal connection will be an interesting task for future studies. In addition, increased DNA
methylation has been suggested to reduce Pol-II elongation speed [145,146] and thus could
further explain the associated transcriptional repression.
However, gene expression involves an intricate time- and context-specific interplay of epi-
genetic mechanisms and transcription factors. Genes that show consistently coupled methyla-
tion and expression changes in both DR and Ames dwarf mice are therefore strong candidates
for further exploration given their robust regulation. For instance, Fgfr3 is an oncogenic medi-
ator of mitogenic signals [94,96,147] and activator of Srebf1-mediated lipogenesis [99–101].
Down-regulation of Fgfr3 could thus be a candidate mechanism for exploring the signaling
effects of both dwarfism and DR. Critically, in-vitro knockdown of Fgfr3 not only mimicked
the DR-like repression of lipogenesis, but also DR-induced up-regulation of transcriptional
regulators like Jdp2 [148], Nfkbia [149] and Arnt [150]. Epigenetic reprogramming of Fgfr3
could therefore exert extensive downstream effects, which may contribute to improved health
during ageing.
Conclusion
This study provides novel insights into the effects of longevity interventions on DNA methyla-
tion and how they may causally contribute to improved health at old age. Dietary restriction
(DR), rapamycin treatment and reduced somatotropic signaling remodel DNA methylation
partly independent of ageing, converging on defined marker regions predictive of intervention
outcome. In addition, DR and rapamycin treatment resemble separate hypermethylation pat-
terns of Ames dwarf mice, affecting lipid metabolism and growth factor signaling genes,
respectively. For DR and Ames dwarf mice, we furthermore demonstrate significant associa-
tion between DNA methylation and gene expression. Therefore, our work establishes hyper-
methylation signatures as a link between the long-term effects of several longevity models and
their transcriptional networks controlling somaotropic signaling and metabolism.
Methods
Ethics statement
The study involving live mice was performed in strict accordance with the recommendations
and guidelines of the Federation of the European Laboratory Animal Science Association
(FELASA), with all protocols approved by the Landesamt fu¨r Natur, Umwelt und Verbrau-
cherschutz, Nordrhein-Westfalen, Germany (reference number: 84–02.04.2015.A437). For
dissections mice were killed by cervical dislocation.
Bisulfite Amplicon sequencing
Bisulfite Amplicon sequencing (BS-AS) libraries were prepared from liver tissue of 24 months
old female C3B6F1♀ mice with the following treatment groups: 5 DR or 5 AL fed mice (for ani-
mals husbandry see [49]), 4 homozygous IRS1-mutant and 4 wild-type mice. DNA was iso-
lated using the DNA/RNA Allprep kit (Qiagen) and bisulfit conversion was done using the
Imprint DNA modification kit (Sigma) following the one-step modification procedure. The
KAPA HiFi Uracil+ Master Mix kit (Kapa Biosystems) was used to amplify the 4 regions of
interest using the primers indicated in S23 Table. A single round of PCR amplification was
used per sample whereby the forward primer contained a 6bp sample barcode. The PCR pro-
gram was: 95C 5min; 35 repeats of 98˚C 20s, 60˚C 15s, 72˚C 60s; 72˚C 10min. PCR products
were purified using Ampure XP beads (Agencourt), analyzed on a 4200 Tape station system
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(Agilent) and subsequently pooled for library preparation. Two libraries were generated with
40 and 32 samples for the AL vs. DR and IRS-1 vs. wild-type comparison, respectively.
Sequencing was performed using 250bp paired end reads on an Illumina HiSeq2500.
WGBS-seq quantification and differential methylation analysis
An overview of the analyzed datasets and treatment conditions is given in (S1 Table). Raw
datasets were downloaded from the GEO repository under accession IDs GSE89275 and
GSE92486. WGBS-seq data were preprocessed and analyzed according to [49]. Raw sequence
reads were trimmed using Trim Galore! (v0.4.2). Trimmed sequences were aligned using Bis-
mark [151] (v0.16.3). Methylation calls were extracted after duplicate sequences had been
excluded. Data visualization and analysis were performed using SeqMonk and custom RStudio
scripts. Each age and treatment group was present in biological triplicates or quadruplets.
Data from replicates of the same treatment group were merged using SeqMonk’s data group
option, in order to enhance coverage and detection of subtle differences. The high consistency
between replicates across the used datasets has been previously verified in the original studies
[49,50]. Regions with an unusually high number of observations were detected and filtered
using non-overlapping 25 kb windows, followed by read count quantification and subsequent
BoxWhisker filter implemented in SeqMonk with stringency >10. To achieve a fair and unbi-
ased analysis of the methylome, we constructed windows containing 50 CpGs over the whole
genome, spaced 25 CpGs apart. To demonstrate the validity of our findings independent of the
window size, we partly repeated the analyses with windows containing 20 or 10 CpGs, spaced
10 and 5 CpGs apart, respectively. Each window therefore contained around the same amount
of data and all windows had similar technical noise and statistical power. Furthermore, to
reduce the effect of coverage differences between samples, only cytosines covered by at least
three observations in all analyzed treatment groups were used for window construction,
opposing the limitation for total number of bins and resulting bin size. Methylation for each
window was calculated as the average of methylation for each covered CpG position. Windows
that contained significantly different methylation levels (pairwise Chi-squared tests with subse-
quent multiple testing correction; adjusted p-value <0.05) and a minimal difference cutoff of
10% were defined as differentially methylated (DMR) [49].
Filtering of CpGs and binning was conducted for each of the following analyses separately:
a) Old DR treated C3B6F1♀ or UM-HET3♀ mice including controls (Fig 1) b) old DR fed
C3B6F1♀, Ames dwarf and rapamycin treated UM-HET3♀ mice, including controls (Fig 2) c)
young and old C3B6F1♀, Prop1♂, UM-HET3♀ control mice (S2 Fig) d) young DR fed
C3B6F1♀ and Ames dwarf mice, including controls (S3 Fig).
For the example in S2C, the methylation landscape over the Tat gene locus was visualized
by calculating average CpG methylation levels of 500 bp 400 bp overlapping bins to improve
resolution.
Comparative DMR analysis
Significance of DMR sets common between two interventions was tested using Fisher’s exact
test with the entire methylome as background. Due to the observed gene body-wide methyla-
tion profiles, differentially methylated genes were defined as common when overlapped by at
least two DMRs in each intervention (not necessarily the identical DMRs). For comparing lon-
gevity-related DMRs with age-effects (S3A Fig), we selected every bin overlapping age-related
DMRs detected in at least two strains as reference. To test if methylation differences induced
by two interventions would be associated in general, we asked if significant DMRs detected in
one intervention would correlate with methylation changes in another intervention,
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independent of statistical significance. To this end, we selected DMRs detected in DR treated
C3B6F1♀ mice and plotted the observed methylation differences for the same bins in other
interventions (DR, rapamycin and dwarfism). The number of bins within the four resulting
quadrants was counted and directionality of differences was tested using one-sided Fisher’s
exact test.
Enrichment analyses of DMRs over genomic and epigenetic elements
For a given genomic element, we calculated the enrichment for a set of DMRs by counting the
number of DMRs overlapping the element of interest and compared it to the set of background
bins. One-sided Fisher’s exact test with subsequent multiple testing correction (if enrichment
analysis was run over multiple elements) was performed to determine statistical significance of
enrichment. Since most elements showed highly significant enrichment, we log-transformed
the adjusted p-values. Ratio of the observed DMR frequency and the average frequency across
the genome (‘observed/expected’) for individual elements were used to compare enrichments
across elements and between DMR sets. This way, we were able compare the strengths of
enrichments across elements in the same analysis.
RRBS-seq quantification and differential methylation analysis
Raw datasets were downloaded from the GEO repository under accession ID GSE80672. Raw
sequence reads were trimmed using Trim Galore! (v0.4.2). Trimmed sequences were aligned
using Bismark [151] (v0.16.3). Data visualization and analysis were performed using SeqMonk
and custom RStudio scripts. Data from replicates of the same treatment group were merged
using SeqMonk’s data group option, in order to enhance coverage and detection of subtle dif-
ferences. To reduce the effect of coverage differences between samples, only cytosines covered
by at least five observations were used for the differential methylation analysis. Differentially
methylated cytosines (dCpGs) were identified by pairwise Chi-squared tests with subsequent
multiple testing correction (adjusted p-value <0.05) and a minimal difference cutoff of 10%.
Filtering of CpGs and binning was conducted for old DR treated C57BL/6♂ or B6D2F1♂ mice
including controls (S1 Fig).
Functional enrichment analyses of differentially methylated genes
For the analyses employing WGBS-seq data, we performed functional enrichment of genes
overlapped by at least two DMRs and only retained those showing at least ±10% average differ-
ence. We thereby avoided unclear cases with an equal extent of hyper- and hypomethylation
occurring over the same gene. Enrichment analysis was carried out using topGO [152] and
ReactomePA [153] with all genes in the genome as background.
For the analyses employing RRBS-seq data, we tested each gene for significant enrichment
of overlapping dCpGs compared to all detected CpGs overlapping and only retained those
with p-values < 0.05 from Fisher’s exact test (after multiple testing correction) and at least
±10% average difference.
Marker regions of longevity analysis
We quantified the methylation for each CpG position individually that mapped within the
four hypermethylated DMRs shared between all three longevity interventions but not with
age-related hypomethylation (S3A Fig). CpGs covered by at least three observations in at least
one analyzed treatment group was included and the methylation change across CpGs tested
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using paired Wilcoxon rank-sum test. The analysis was repeated after manually selecting one
representative 500 bp regions for each of the four DMRs.
BS-AS quantification and differential methylation analysis
Raw sequencing libraries were de-multiplexed before mapping and methylation extraction was
conducted as described for WGBS-seq. De-duplication step was omitted. Data visualization
and analysis were performed using SeqMonk and custom RStudio scripts. Data from replicates
of the same treatment group were averaged using SeqMonk’s replicate set option. To reduce
the effect of coverage differences between samples, only cytosines covered by at least three
observations were used for the differential methylation analysis. Differentially methylated
cytosines (dCpGs) were identified by pairwise, replicate-sensitive logistic regression tests with
subsequent multiple testing correction (adjusted p-value <0.05). Methylation change across
CpGs was tested using paired Wilcoxon rank-sum test.
RNA-seq analysis
For young and old Ames dwarf and DR-fed C3B6F1♀ mice, RNA-seq data derived from liver
tissue of the same animals used for WGBS-seq was downloaded from the GEO repository
under accession IDs GSE89275 and GSE92486 (S1 Table). Two replicate samples of young
Ames dwarf mice showed very high amounts of low quality reads and insufficient coverage
and were therefore removed from the analysis. Raw sequence reads were trimmed to remove
adaptor contamination and poor-quality reads using Trim Galore! (v0.3.7, parameters:—
paired—length 25). Trimmed sequences were aligned using Tophat2 [154] (v2.0.14, parame-
ters:—no-mixed—library-type = fr-firststrand -g 2 -p 15 -r 500—mate-std-dev 525), supplying
GENCODE annotation [155] (release M9, main annotation) for improved mapping. Multi-
mapped reads were filtered using samtools [156] (v1.2, parameters: view -F 0x100 -b–h). Data
visualization and analysis was performed using SeqMonk, custom RStudio scripts and the fol-
lowing Bioconductor packages: Deseq2 [157], topGO [152], ReactomePA [153] and org.Mm.
eg.db. For Figs 4B, S5B, S6B and S7C, we further used the CellPlot package (https://github.
com/dieterich-lab/CellPlot). To account for tissue-specific expression, we defined all genes
passing the independent filtering of Deseq2 [157] as ‘expressed’ (14154 and 13894 genes for
C3B6F1♀ and Prop1♂ mice, respectively). Differentially expressed genes were determined
using Deseq2´s Wald test [157]. P-values were adjusted for multiple testing. Genes were con-
sidered to be significantly differentially expressed with a p adjust < 0.05 and no cut-off for fold
change was used. Unless stated otherwise, the set of expressed genes was used as background
for all functional enrichment analyses involving expression data.
Correlation analysis of methylation and transcription
To test for correlation between differential methylation and gene expression, we considered
only genes overlapped by at least two DMRs. For associations between differential methylation
over uiDMRs and expression, we considered only genes with their uiDMRs (0.3–8 Kbp down-
stream of gene start) overlapped by at least one DMR. We averaged methylation differences
for multiple DMRs overlapping the same gene (uiDMR) before plotting, and only retained
those showing at least ±10% average difference. We thereby avoided unclear cases with an
equal extent of hyper- and hypomethylation occurring over the same gene (uiDMR). We plot-
ted log2-fold expression changes versus methylation differences and the distribution of genes
among the four resulting quadrants. Due to the very few hypomethylated genes common
among longevity interventions, we focused on hypermethylated genes for statistical testing.
For the group of differentially expressed and hypermethylated genes above the minimum
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methylation cut-off, we ran a binomial test to probe for a significant trend towards down- or
up-regulation. Genes that showed a significant association of hypermethylation and transcrip-
tional repression were analyzed for functional enrichment using topGO [152].
Comparative transcriptome analysis for DR liver tissue and Fgfr3
knockdown in RT112 cells
To compare the transcriptional changes induced by DR with in-vitro knockdown of Fgfr3, we
obtained a list of Fgfr3-regulated genes from pre-preprocessed microarray results from [100].
The list comprises significantly differentially expressed genes in three independent doxacy-
cline-treated RT112 cell lines expressing doxycycline-inducible shRNAs targeting Fgfr3 (each
cell line expresses another Fgfr3-shRNA). Gene expression was compared to a line expressing
a control shRNA [100]. For each gene showing differential expression in Fgfr3 knockdown
cells and liver tissue of DR-treated mice, we plotted log2-fold expression changes under DR
(compared to ad libitum feeding) versus log2-fold expression changes under Fgfr3 knockdown
(compared to control). We plotted the distribution of genes among the four resulting quad-
rants and tested for directionality using Fisher’s exact test.
Definition of genomic and epigenetic elements
Gene annotation used in this study was obtained from the UCSC Genome Browser database
[158]. We defined further genome annotation as follows:
Promoter region: Manually defined region stretching from 5 Kbp upstream and 100 bp down-
stream of the transcription start site.
uiDMR: According to [89], uiDMRs were defined as regions stretching from 300 to 8000 bp
downstream of the transcription start site. Analysis was limited to genes with a total size of
at least 16 Kbp.
CGI: Annotation based on CXXC affinity purification plus deep sequencing (CAP-seq) experi-
ments [159] CGIs were further classified unambiguously into promoter, gene and inter-
genic CGIs. If a CGI overlapped both promoter and gene body, it was classified as a
promoter CGI.
Chromatin states: Publicly available, pre-processed chromatin annotation in liver tissue based
on four histone marks (ENCODE chromHMM segmentation) were obtained from the
ENCODE table browser [60] and re-mapped to the GRCm38 genome using UCSC Genome
Browser’s LiftOver [160]. Details about the corresponding methods can be found here:
https://main.genome-browser.bx.psu.edu/cgi-bin/hgTrackUi?g=meryChromHmm7s&db=
mm9).
Supporting information
S1 Fig. Dietary restriction-related methylation changes are tissue-specific. (A) Schematic
representation of the data sets analysed and comparisons made. We probed for Dietary
Restricted (DR)-related dCpGs in blood of adult B6D2F1♂ and C57BL/6♂. Pre-processing
was conducted in parallel for all experimental groups (B) Number of dCpGs (p<0.05, ±10%<
DNA methylation difference) between each DR cohort and its respective control. Proportion
of hypermethylated dCpGs are indicated in %. (C) Venn diagrams depicting the overlap of sig-
nificantly hypo- and hypermethylated dCpGs in both DR cohorts. Proportions of overlap rela-
tive to the C57BL/6♂ set are indicated in % (p-values; ��� p<0.001, �� p<0.01, � p<0.05,
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Fisher’s exact test). (D,E) Edwards-Venn diagrams depicting the overlap of significantly hypo-
(E) and hypermethylated (D) genes in liver (see Fig 1) and blood present in the four tested DR
cohorts. Liver and blood datasets are indicated by solid and dashed lines, respectively.
(TIF)
S2 Fig. Validation of fixed-CpG binning approach. (A) Histogram of bin lengths for the
comparison in Fig 2B using bins covering 50, 20 or 10 CpGs. For illustrative purpose, the first
histograms were calculated for> 90% of all bins. Mean and median bin lengths are indicated
by black and green lines, respectively. (B) Number of DMRs (p<0.05, ±10%< DNA methyla-
tion difference) between each longevity intervention and it’s respective control using bins
covering 50, 20 or 10 CpGs. Proportion of hypermethylated DMRs are indicated in %. (C)
Scatterplot representation of methylation values of each 10-CpG bin in control and long-lived
animals. Intervention-related DNA methylation changes are highlighted. Bins that were not
differentially regulated (background) are represented in grey. Data density is indicated by
color code.
(TIF)
S3 Fig. Conservation of hypermethylation patterns is independent of window size. (A)
Venn diagram depicting the overlap of significantly hypermethylated DMRs under DR,
Dwarfism and rapamycin treatment relative to the control groups at old age using bins cover-
ing 50, 20 or 10 CpGs (p-values; ��� p<0.001, �� p<0.01, � p<0.05, Fisher’s exact test). (B)
Enrichment analysis of common hypermethylated 10-CpG-DMRs over common hypermethy-
lated DMRs detected with 50-CpG bins. Bars indicate the ratio of the observed DMR fre-
quency and the average frequency across the genome (log2-transformed; adjusted p-values; ���
p<0.001, �� p<0.01, � p<0.05, Fisher’s exact test). (C) Venn diagram depicting the overlap of
significantly hypomethylated DMRs under DR, Dwarfism and rapamycin treatment relative to
the control groups at old age using bins covering 50, 20 or 10 CpGs (p-values; ��� p<0.001, ��
p<0.01, � p<0.05, Fisher’s exact test).
(TIF)
S4 Fig. Enrichment analysis of intervention-related DMRs with increased resolution.
(A-C) Enrichment analysis of common hypermethylated 10-CpG-DMRs between DR and
Dwarfs (n = 6679) and rapamycin treatment and Ames dwarf mice (n = 4355) over genomic
elements (A), ENCODE chromatin states (B) and Cistrome binding sites of DNA binding ele-
ments (C). Bars indicate the ratio of the observed DMR frequency and the average frequency
across the genome (log2-transformed; adjusted p-values; ��� p<0.001, �� p<0.01, � p<0.05,
Fisher’s exact test). (D) Differential methylation landscape of the Elovl6, Egf, Ghr, and Egfr
gene loci using 10-CpG bins. Bins are represented as bars with color scale and height indicat-
ing methylation differences. Shaded area indicates location of 50-CpG-DMRs for comparison.
Arrows indicate gene orientation; merged mRNA structure is depicted below.
(TIF)
S5 Fig. Functional enrichment analysis of intervention-related DMRs. Functional enrich-
ment of differentially hyper- and hypomethylated genes in DR-treated mice (A), rapamycin-
treated mice (B) and Ames dwarf mice (C) at old age in comparison to respective controls.
(TIF)
S6 Fig. Cross-strain hepatic DNA methylation changes in response to ageing. (A) Sche-
matic representation of data sets and comparisons made. We analyzed age-related DMRs,
comparing old and young control mice for each strain separately. Pre-processing was con-
ducted in parallel for all groups (B) Boxplot representation of global DNA methylation levels
DNA methylation and lifespan-extending interventions
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007766 November 21, 2018 24 / 37
in the liver of young and old C3B6F1♀, heterozygous Prop1 mutant and UM-HET3♀ mice.
Strain and sex are indicated above. (C) Number of significantly differentially methylated
regions (age-related DMRs) (p<0.05, ±10%< DNA methylation difference) in response to age
in three different mouse strains. Proportion of hypermethylated DMRs are indicated in %. (D)
Scatterplot representation of methylation values of each bin in young and old animals com-
pared across strains. Age-related DNA methylation changes are highlighted. Bins that were
not differentially regulated (background) are represented in grey. Data density is indicated by
color code. (E,F) Venn diagram depicting the overlap of significantly age-related hypo- (E)
and hypermethylated (F) DMRs across mouse strains. The set of age-related DMRs detected in
at least two strains are highlighted in grey (p-values; ��� p<0.001, �� p<0.01, � p<0.05, Fisher’s
exact test).
(TIF)
S7 Fig. Longevity intervention-related differential methylation is initiated at young age
and does not result from retardation of ageing alone. (A) Venn diagram depicting the over-
lap of bins located over hypomethylated age-related DMRs with hypermethylated DMRs com-
mon between DR, dwarfism and rapamycin treatment (p-values; ��� p<0.001, �� p<0.01, �
p<0.05, Fisher’s exact test). (B) Schematic representation of data sets and comparisons. We
probed for intervention-related DMRs at young age, by comparing long-lived mice to their
respective controls. Pre-processing was conducted in parallel for all shown treatment groups.
(C) Number of DMRs (p<0.05, ±10%< DNA methylation difference) between young DR or
young Dwarf mice and their respective controls. Proportion of hypermethylated DMRs are
indicated in %. (D) Scatterplot comparison of bin-wise differences between Young DR-related
DMRs versus changes in young Dwarf mice, respectively. Bins overlapping the Scd1 gene are
highlighted in red. Methylation differences under DR were significantly positively associated
with differences in Ames dwarf mice (One-sided Fisher’s exact test p< 0.01). Number of bins
in each quadrant is indicated in blue. (E) Enrichment analysis of hypermethylated DMRs
under young DR or young Dwarf mice over longevity-related DMRs detected at old age. Bars
indicate the ratio of the observed DMR frequency and the average frequency across the
genome (log2-transformed; adjusted p-values; ��� p<0.001, �� p<0.01, � p<0.05, Fisher’s exact
test). (F,G) Venn diagram depicting the overlap of hypermethylated genes (� 2 DMRs overlap-
ping) under young DR, young Ames dwarf and (F) old DR or (G) old Ames dwarf mice,
respectively (p-values; ��� p<0.001, �� p<0.01, � p<0.05, Fisher’s exact test). (H,I) Differential
methylation landscape of the Scd1 (H) and Elovl6 (I) gene loci in DR or Ames dwarf mice at
young age. Bins are represented as bars with color scale and height indicating methylation dif-
ferences. Arrows indicate gene orientation; merged mRNA structure is depicted below.
(TIF)
S8 Fig. Concerted CpG hypermethylation in four distinct DMRs occurs in response to DR,
reduced somtaotropic signaling and rapamycin-treatment. (A) Pictographic representations
of chromosome 8 with intervention-related DMRs indicated by colored bars. Highlighted is a
DMR common among all three models that was not detected as age-related DMR. (B) The
shaded area indicates the hypermethylated DMR common among all three longevity models
mapping over the Tat gene locus. For improved resolution, the methylation profile is repre-
sented by 500 bp bins overlapping adjacent bins by 400 bp. Arrows indicate gene orientation;
merged mRNA structure is depicted below. (C) DNA methylation levels of single cytosines
(points) present in four longevity-related, age-independent DMRs in the liver of aged DR
(C3B6F1♀ and UM-HET3♀), Ames Dwarf and Rapamycin treated mice next to their respective
controls. Lines represent the methylation change over individual cytosines. Colored boxplots
represent methylation levels averaged across all cytosines (p-values; ��� p<0.001, �� p<0.01, �
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p<0.05, Paired Wilcoxon rank-sum test).
(TIF)
S9 Fig. Methylation levels at 125 cytosines are correlated with longevity. (A) DNA methyla-
tion levels of single cytosines (points) present in four longevity intervention-related, age-inde-
pendent 500 bp regions in the liver of aged DR (C3B6F1♀ and UM-HET3♀), Ames Dwarf and
rapamycin-treated mice next to their respective controls. Lines represent the methylation
change over individual cytosines. Colored boxplots represent methylation levels averaged
across all cytosines (p-values; ��� p<0.001, �� p<0.01, � p<0.05, Paired Wilcoxon rank-sum
test). (B) DNA methylation levels over the same set of cytosines in young and old controls
(p-values; ��� p<0.001, �� p<0.01, � p<0.05, Paired Wilcoxon rank-sum test). (C) DNA meth-
ylation levels over the same set of cytosines in young Ames dwarf and DR (C3B6F1♀) mice
next to their respective controls (p-values; ��� p<0.001, �� p<0.01, � p<0.05, Paired Wilcoxon
rank-sum test). (D) DNA methylation levels over the same set of cytosines measured by RRBS-
seq in blood of adult DR (B6D2F1♂) mice next to their respective controls. The dashed
box indicates the range of methylation levels that is not covered by RRBS-seq data in blood.
(TIF)
S10 Fig. Verification of longevity marker by Bisulfite Amplicon sequencing (BS-AS). (A)
CpG-wise DNA methylation at the four targeted DMRs as measured by BS-AS in exemplary
Irs1KO replicate. DNA methylation as measured by WGBS-seq (Dietary restriction) is dis-
played on top for comparison. Target DMRs and surrounding genes and CGIs are highlighted.
Genomic location of the marker regions are listed in the table above (B) Heatmap of unsuper-
vised clustering of CpG-wise methylation changes as measured by BS-AS (n = 4–5 replicates
per group; color bar represents z-score range). Additionally, replicates of the same treatment
group were averaged and provided as additional sample for comparison with individual repli-
cates. Clustering of CpGs dependent on region (rows) and treatment group (columns) are
highlighted. White box indicates Region III. (C,D) DNA methylation levels of single cytosines
(points; n = 80) present in (C) four or (D) three longevity-related, age-independent DMRs in
the liver of aged DR fed (C3B6F1♀) and Irs1-KO mice next to their respective controls. Lines
represent the methylation change over individual cytosines. Red lines indicate dCpGs with
higher methylation levels in long-lived mice; green lines indicate dCpGs with lower methyla-
tion levels. Colored boxplots represent methylation levels averaged across all cytosines (p-val-
ues; ��� p<0.001, �� p<0.01, � p<0.05, Paired Wilcoxon rank-sum test).
(TIF)
S11 Fig. Dwarfism-related DNA methylation differences predict expression changes in
young animals. (A) Scatterplot of expression differences versus methylation differences of
dwarfism-related DMRs at young age. Dashed lines indicate DNA methylation cutoff of>
±10%. DNA hypermethylation associated significantly with reduced gene expression (Bino-
mial test p< 0.001). Number of differentially methylated genes in each quadrant is indicated
in blue and red, for all genes and differentially expressed genes, respectively. (B) Gene ontology
and Reactome enrichment of genes with a negative correlation of gene expression and methyl-
ation. Lengths of bars represent negative ln-transformed, adjusted pvalues using Fisher’s exact
test. Cells indicate log2-foldchanges (log2FC) between Ames dwarf and controls per gene. (C)
Venn diagram depicting the overlap of genes with a negative correlation of gene expression
and methylation in young and old Ames Dwarf mice (p-values; ��� p<0.001, �� p<0.01, �
p<0.05, Fisher’s exact test). (D,E) Scatterplot of expression differences versus methylation dif-
ferences of dwarfism-related DMRs mapping uiDMRs at (D) young and (E) old age. Dashed
lines indicate DNA methylation cutoff of> ±10%. DNA hypermethylation associated
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significantly with reduced gene expression (Binomial test p< 0.001). Number of differentially
methylated genes in each quadrant is indicated in blue and red, for all genes and differentially
expressed genes, respectively.
(TIF)
S12 Fig. DR and genetic dwarfism commonly regulate methylation and expression of
Fgfr3. (A) Scatterplot of expression differences versus methylation differences of DR-related
DMRs. Dashed lines indicate DNA methylation cutoff of> ±10%. DNA hypermethylation
associated significantly with reduced gene expression (Binomial test p< 0.05). Number of dif-
ferentially methylated genes in each quadrant is indicated in blue and red, for all genes and dif-
ferentially expressed genes, respectively. (B) Gene ontology and Reactome enrichment of
genes with a negative correlation of gene expression and methylation. Lengths of bars repre-
sent negative ln-transformed, adjusted pvalues using Fisher’s exact test. Cells indicate log2-
foldchanges (log2FC) between DR mice and control group per gene. (C,D) Venn diagrams
depicting the overlap of genes being transcriptionally (C) down- or (D) up-regulated in DR or
Ames dwarf mice, respectively. Both down- and up-regulated genes showed a significant over-
lap between both longevity models (p-values; ��� p<0.001, �� p<0.01, � p<0.05, Fisher’s exact
test). (E) Venn diagram depicting the overlap of genes being transcriptionally down-regulated
and hypermethylated in DR and Ames dwarf mice. (F) Differential methylation landscape of
the Fgfr3 gene locus in DR, Rapamycin treated and Ames dwarf mice. Bins are represented as
bars with color scale and height indicating methylation differences. Arrows indicate gene ori-
entation; merged mRNA structure is depicted below. (G) Fgfr3 mRNA expression by RNA-
sequencing in control and Ames Dwarf mice at young and old age, respectively (n = 4 vs 2 and
4 vs 4). (H) Fgfr3 mRNA expression by RNA-sequencing in control and DR mice at young
and old age, respectively (n = 3 vs 3 and 3 vs 3).
(TIF)
S13 Fig. In-vitro knockdown of Fgfr3 regulates lipid metabolism similar to DR in-vivo. (A)
Venn diagram depicting the overlap of genes differentially expressed in livers of DR treated
mice and RT112 cells transfected with short-hairpin RNA targeting Fgfr3 (p-values; ���
p<0.001, �� p<0.01, � p<0.05, Fisher’s exact test). (B) Scatterplot of expression differences in
livers of DR treated mice versus expression differences in RT112 cells with induced Fgfr3
knockdown. Number of differentially expressed genes in each quadrant is indicated in blue
with common expression changes highlighted in red. Both transcriptomes showed signifi-
cantly common expression signatures (p< 0.01, Fisher’s exact test). (C) Gene ontology and
Reactome enrichment of genes being commonly regulated in DR treated mice and RT112 cells
with induced Fgfr3 knockdown. Lengths of bars represent negative ln-transformed, adjusted
pvalues using Fisher’s exact test. Cells indicate log2-foldchanges (log2FC) between DR mice
and control group per gene.
(TIF)
S1 Table. Overview of datasets used in this study.
(XLSX)
S2 Table. List of DR-related DMRs in two strains.
(XLSX)
S3 Table. Functional enrichment of genes associated with identical DR-related DMRs in
two strains.
(XLSX)
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S4 Table. Functional enrichment of genes associated with DR-related hypermethylation in
two strains.
(XLSX)
S5 Table. List of DR-, rapamycin-, and dwarfism-related DMRs at old age.
(XLSX)
S6 Table. Functional enrichment of genes associated with differential methylation in
female DR fed C3HB6F1 mice.
(XLSX)
S7 Table. Functional enrichment of genes associated with differential methylation in
female rapamycin-treated UM-HET3 mice.
(XLSX)
S8 Table. Functional enrichment of genes associated with differential methylation in male
Ames dwarf mice.
(XLSX)
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